AI주식인사이트AI Stock Insight
C

경보제약

214390KOSPI기초 의약물질 제조업

52.0 / 100

Reference Date: 2026-07-24

Financial Score15.0 / 40
News Sentiment20.0 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 1.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongbo Pharm, established in 1987, is a specialty pharmaceutical company specializing in raw material drugs, selling cardiovascular medications, inhalation anesthetics, and general pharmaceuticals. With raw material pharmaceuticals revenue at 137.3 billion KRW and finished pharmaceuticals at 96.8 billion KRW in 2024, the company is preparing to enter the global ADC CDMO market through self-developed technology. It also expands into medical devices and animal health sectors.

Number of Employees

571people

Average Salary

75.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
636.25Industry Average 25.440.0Point

25.0x industry avg (risky)

PBR
0.83Industry Average 1.265.5Point

Lower than industry avg (good)

ROE
0.13Industry Average -6.033.5Point

Well below industry avg

Debt Ratio
18.22Industry Average 6.620.0Point

2.8x industry avg (risky)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲10.5% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲11.1% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 1.8% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 5,090Won52-week high 8,55052-week low 4,825
1-month return3.0Point

1m 1.19% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral지속가능경영보고서등관련사항(자율공시)2026-06-26